Woburn, MA - April 21, 2005 - The Center for Business Intelligence announces its Obesity Drug Development Summit

The Center for Business Intelligence (CBI) holds the Obesity Drug Development Summit on July 21-22, 2005 at Sheraton National in Arlington, VA.

Industry speakers from Amgen, AstraZeneca, sanofi-aventis, Johnson & Johnson, Wyeth Research, Merck Research Laboratories and other leading companies provide clinical results and case studies at this featured event for CBI's Business of Discovery Series.

Hear an FDA Address on "A historical perspective on the current regulation of Obesity drugs in the U.S." and a CDC Address on "Obesity as a world pandemic"

In 2004, US spent $75 billion from public sources on medical expenditures attributable to Obesity. The FTC estimates that we spend $35 billion per year on weight loss products and programs. Impressive advances have been made in the areas of molecular genetics and the molecular physiology of the control of body weight and composition. However these advances have not yet translated into successful therapeutic approaches to the disease of Obesity.

This summit highlights the current scientific advances and the current status of therapeutic treatments for the chronic disease of obesity, as well as analyzes market opportunities to address this important unmet medical need.

Outstanding support provided by: PharmaVOICE, Current Diabetes Reviews, Current Nutrition & Food Science, PharmCast, Treatments in Endocrinology, Drug Discovery & Development and D&MD Publications.

For more information on this event or to register, contact CBI Registration at 800-817-8601 Fax 781-939-2490 Email cbireg@cbinet.com. Please visit us online at http://www.cbinet.com/show_conference.cfm?confCode=HB549